Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression
Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression
复制标题
DOI：
10.4088/jcp.18m12137
复制
发表时间：
2018-09-01
影响因子：
5.3
通讯作者：
Taylor, Warren D.
中科院分区：
文献类型：
--
作者：
Gandelman, Jason A.;Kang, Hakmook;Taylor, Warren D.
目的：老年抑郁症（LLD）是以抗抑郁反应差和认知功能障碍为特征的一种抑郁症。本研究探讨了透皮尼古丁是否有益于LLD.Methods的情绪症状和认知表现：在2016年11月至2017年8月进行的为期12周的开放标签门诊研究中，15名不吸烟的老年人（>= 60岁）接受了透皮尼古丁治疗。合格的参与者符合DSM-IV-TR重度抑郁症标准，蒙哥马利-阿斯伯格抑郁量表（MADRS）>= 15，并认可主观认知障碍。每日使用经皮尼古丁贴剂，并按照严格的剂量递增策略滴定至最大剂量21.0 mg/d，允许因耐受性而降低剂量。主要的情绪结果是每3周测量一次MADRS变化，反应定义为从基线改善≥ 50%，缓解定义为MADRS评分
Objective: Late-life depression (LLD) is characterized by poor antidepressant response and cognitive dysfunction. This study examined whether transdermal nicotine benefits mood symptoms and cognitive performance in LLD.Methods: In a 12-week open-label outpatient study conducted between November 2016 and August 2017, transdermal nicotine was given to 15 nonsmoking older adults (>= 60 years of age). Eligible participants met DSM-IV-TR criteria for major depressive disorder with >= 15 on the Montgomery-Asberg Depression Rating scale (MADRS) and endorsed subjective cognitive impairment. Transdermal nicotine patches were applied daily and titrated in a rigid dose escalation strategy to a maximum dose of 21.0 mg/d, allowing dose reductions for tolerability. The primary mood outcome was MADRS change measured every 3 weeks, with response defined as >= 50% improvement from baseline and remission as MADRS score